Skip to content
StockMarketAgent
Direct answer
CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $382, high $743, with mid-point at $561.
Stock analysis

CI CI fair value $382–$743

CI
By StockMarketAgent.AI team· supervised by
分析日: 2026-05-12次回更新: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
株価
$289.07
▲ +272.29 (+94.20%)
公正価値
$561
$382–$743
評価
強い買い
confidence 83/100
上昇余地
+94.2%
upside to fair value
安全余裕率
$477.16
MoS level · 15%
時価総額
$76.5B
P/E fwd 8.6
英語版にフォールバックJA
翻訳中のため英語版を表示しています
このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

§1 エグゼクティブサマリー

  • Composite fair value $561 with high case $743.
  • Implied upside of 94.2% to fair value.
  • Moat 9/10 · confidence 83/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$561
Margin of safety
+48.5%
Confidence
83/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$289.07Price
Low $382.18
Mid $561.36
High $742.98

CI trades against a final fair-value range of $382.18-$742.98, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Evernorth scale and specialty pharmacy
    Evernorth scale and specialty pharmacy dominance
  • Vertical integration of PBM and
    Vertical integration of PBM and health benefits
  • Cycle upside
    Consolidation of specialty pharmacy and managed care services driving scale efficiencies.

§2 ベアケース

Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.

このテーゼが崩れる経路

PBM Spread Pricing Ban

· High

Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.

FV impact
Moderate to Severe
Trigger
12-24 months

Medical Cost Spike

· Medium

Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.

FV impact
Moderate
Trigger
6-12 months

De-leveraging Failure

· Low

Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.

FV impact
Severe
Trigger
24-36 months
監視すべき早期警戒シグナル
指標現在トリガーしきい値
Operating margins sustainably compressing toward the 3.0% industry median over 4 consecutive quarters.MonitorDeterioration versus the report thesis
Total corporate revenue actively dropping into negative YoY growth territory.MonitorDeterioration versus the report thesis
Unplanned suspension of the share repurchase program.MonitorDeterioration versus the report thesis
Medical care ratio (MCR) exceeding internal targets for two consecutive quarters.MonitorDeterioration versus the report thesis
Key enterprise client losses within the Evernorth segment.MonitorDeterioration versus the report thesis

§3 財務履歴

損益計算書 — 直近6期
項目T−0T−1T−2T−3T−4CAGR
期間2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
売上高$174.27B$180.03B$195.19B$244.38B+8.8%
売上総利益
営業利益
純利益$5.37B$6.70B$5.16B$3.43B-10.6%
EPS (希薄化後)$21.30$17.39$12.12$22.18+1.0%
EBITDA
研究開発
販管費$13.01B$13.17B$14.82B$14.84B+3.3%

品質スコア

OCF / 純利益
3.02×
>1 は利益の質が高いことを示す
会計品質ゲート
Fail
セクター調整後ゲート
ROIC
7.2%
投下資本利益率
セクション 3

Numbers analysis

キャッシュフロー

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

資本配分

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

個人サブスクライバー — §4以降11セクション追加

完全な分析を読む — 11セクション追加。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

カバー対象の全ティッカーの完全なレポート
24か月分の評価アーカイブ
ウォッチリストブリーフィング + 評価変更アラート
任意の言語でのPDF + DOCXエクスポート
無料トライアルを開始
いつでもキャンセル可能。
FAQ

CI — frequently asked questions

  1. Based on our latest analysis, CI looks meaningfully undervalued. The current price is $289 versus a composite fair-value midpoint of $561 (range $382–$743), which implies roughly 94.2% upside to the midpoint.
Related coverage

Names readers of CI also follow

Same archetype: mature-compounder